1. Home
  2. TMQ vs ACIU Comparison

TMQ vs ACIU Comparison

Compare TMQ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$4.63

Market Cap

249.6M

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.01

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
ACIU
Founded
2004
2003
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
249.6M
213.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
TMQ
ACIU
Price
$4.63
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
4.4M
1.4M
Earning Date
09-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,482,957.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$738.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$1.43
52 Week High
$11.29
$4.00

Technical Indicators

Market Signals
Indicator
TMQ
ACIU
Relative Strength Index (RSI) 55.07 50.19
Support Level $4.28 $2.87
Resistance Level $4.78 $3.45
Average True Range (ATR) 0.35 0.31
MACD 0.01 0.03
Stochastic Oscillator 58.96 38.09

Price Performance

Historical Comparison
TMQ
ACIU

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: